Ribociclib 200mg (Ribociclib)

Contact us for more information
Wishlist Compare
Brand nameKisqaliInternational trade namekisqaliActive substanceRibociclibStrength200mgCategoryAnti Cancer

Description of Kisqali 200mg (Ribociclib 200mg)

Kisqali 200mg (Ribociclib 200mg) is an anti-cancer ("antineoplastic") chemotherapy medicine . This medication is classified as a "cyclin-dependent kinase inhibitor."4 and 6 (CDK4/6).
Kisqali 200mg (Ribociclib 200mg) is a targeted (biological) therapy. This group of medicines block the growth and spread of cancer. They target and interfere with processes in the cells that cause cancer to grow.

Medical use /Indication of Kisqali 200mg (Ribociclib 200mg)

Kisqali 200mg (Ribociclib 200mg) is indicated in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer

Mechanism of Action Kisqali 200mg (Ribociclib 200mg)

Some proteins in the body results in cells to develop and divide. In ER positive (ER+), HER2 negative breast cancer, these proteins can turn into overactive and provoke breast cancer cells to develop. Ribociclib works by stopping these proteins, helping to inhibits the cancer cells growing and dividing.
When concomitant use with hormone treatment which stops the effects of oestrogen on cancer cells, Ribociclibsupport to delay the growth of ER+, HER2 negative breast cancer.

Absorption of Kisqali 200mg (Ribociclib 200mg)

peak plasma concentration is 1-4 hr and steady state achieved is 8 days.

Distribution of Kisqali 200mg (Ribociclib 200mg)

Human serum protein bound is 70%

Metabolism of Kisqali 200mg (Ribociclib 200mg)

primarily metabolised by hepatic through CYP3A4 in humans

Excretion of Kisqali 200mg (Ribociclib 200mg)

Kisqali is excreted through feces 69% and urine 23%

Half -life is 32.6 hours.

Side effects of Kisqali 200mg (Ribociclib 200mg)

  • Decreased in blood counts
  • Nausea and vomiting
  • Increased liver enzymes
  • Fatigue
  • Diarrhea
  • Hair loss
  • Decreased kidney function
  • Lack of appetite
  • Rash
  • Fever
  • Itching
  • Insomnia
  • Urinary tract infection.

Precautions of Kisqali 200mg (Ribociclib 200mg)

Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation.

Avoid the combination use with tamoxifen due to increased QT prolongation.

In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.

Drug interaction of Kisqali 200mg (Ribociclib 200mg)

Interaction of Kisqali 200mg (Ribociclib 200mg) with strong CYP3A4 inhibitor will increased Ribociclib exposure in healthy subjects but this combination cannot be avoided, so reduce the dose of Kisqali to 400mg once daily Kisqali 200mg (Ribociclib 200mg) concomitant use with strong CYP3A4 inducers will decreased Ribociclib exposure in healthy subjects by 89% Co administration of midazolam with multiple doses of Kisqali will increased the midazolam exposure by 3.8-fold in healthy subjects.

Contraindication of Kisqali 200mg (Ribociclib 200mg)


Pregnancy of Kisqali 200mg (Ribociclib 200mg)

There are no studies with the use of Kisqali 200mg (Ribociclib 200mg) in pregnant women to inform medicine-associated risks. Hence avoid becoming pregnancy during Jakavi 5mg treatment

Lactation of Kisqali 200mg (Ribociclib 200mg)

Avoid breast feeding during treatment with Kisqali 200mg (Ribociclib 200mg). Excretion into human milk is unknown

Dosage of Kisqali 200mg (Ribociclib 200mg)

The usual dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days

The medicine Kisqali can be administrated with or without food.

Over dosage of Kisqali 200mg (Ribociclib 200mg)

overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.

Storage of Kisqali 200mg (Ribociclib 200mg)

The medicine Kisqali is store at 20℃ to 25℃

Missed dose of Kisqali 200mg (Ribociclib 200mg)

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.

Brand name:
International trade name:
Active substance:
Anti Cancer
21 Tablets
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India